Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] HEA MTC
[SU] CXP
-- WITH PHOTO -- TO BUSINESS, HEALTH, AND MEDICAL EDITORS:
Artelon@ Product Line Under New Ownership, Relocates Operations from
Sweden to U.S.
NASHVILLE, Tenn., Feb. 26, 2014 /PRNewswire/ -- International Life
Sciences, LLC (dba, Artelon@) acquired the assets of Artimplant@ AB in
January 2014 and has relocated operations from Sweden to the United
States. This international relocation allows Artelon@ to more closely
engage its largest customer base and provide additional opportunities
for product development that were not previously available.
(Logo: http://photos.prnewswire.com/prnh/20140226/PH72167LOGO )
Adam Barese now serves as the Chief Executive Officer of the
Organization. After garnering almost two decades of medical industry
experience with Wyeth Pharmaceuticals, in sales, marketing, and sales
management, and as a orthopedic/biologic sales director with Genzyme
in the Biosurgical division, Barese most recently built a multistate
medical distributorship which included the Artelon@ products as part
of his portfolio.
Jim Tyson now serves as the US VP of sales and marketing. Mr. Tyson
is a 25-year veteran of the orthopedic medical device industry,
successful stents at Howmedica as a reconstructive and trauma sales
representative and then as a regional and national sales manager at
SBI, Nutek Orthopedic, and Artimplant@.
Artelon continues to work with many of the worldwide distributors that
previously sold the Artelon@ Tissue Reinforcement products, and is
rapidly expanding the number of U.S. and international
distributorships to provide more substantial and highly qualified
market coverage.
The company will be showcasing its products at multiple upcoming
events, including the American College of Foot and Ankle Surgeons
(ACFAS) this week in Orlando, FL.
Artelon markets and sells the Artelon@ Tissue Reinforcement products
worldwide and will be establishing manufacturing operations in the
United States.
Artelon@ is a unique, degradable biomaterial that serves as a scaffold
for tissue ingrowth and provides temporary support for healing tissue.
Artelon@ was developed specifically for medical applications and has
clinical documentation with long follow-up periods. Thousands of
patients worldwide have been successfully treated with Artelon@
implants.
The key features of Artelon@ are:
-- Serves as a temporary scaffold for the body's own cells while it
degrades and integrates with the body over a six year period
-- Stabilizes and shares load during the healing period providing long
term support for healing tissue
-- Excellent biocompatibility to human tissue
-- Synthetic material eliminates the risk of disease transmission or
collagen reactions
Artelon@ Tissue Reinforcement is intended for use in general surgical
procedures for reinforcement of soft tissue. It is also intended for
reinforcement of soft tissues that are repaired by sutures or suture
anchors, during tendon and ligament repair surgery.
Contact: Artelon Adam Barese Chief Executive Officer (01) 615-783-1712
Email www.Artelon.com
Read more news from Artelon.
SOURCE Artelon
-0- 02/26/2014
/Photo: http://photos.prnewswire.com/prnh/20140226/PH72167LOGO
PRN Photo Desk, photodesk@prnewswire.com
CO: Artelon
ST: Tennessee
IN: HEA MTC
SU: CXP
PRN
-- PH72167 --
0000 02/26/2014 13:30:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
